← boardnext 2027-06next 2027-08next 2027-08next 2028-02
ASND
Ascendis Pharma A/Sdistress 0/10 · well-funded / low risk$252.40+0%today-9% from 52w high
Oncology 1
Lead: Achondroplasia · target PD-1
Revenue
$247M
Liquidity
$596M
Runway
—
Shares 1y
0%
Price & events
+10.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
-2.8%
1W
+5.8%
1M
+12.2%
3M
+7.2%
6M
+48.3%
1Y
+87.3%
2Y
+118.2%
5Y
+52.5%
All
Overview
- Market Cap
- $15.64B
- Enterprise Value
- $15.46B
- Volume
- 9.00K
- 52 Week Range
- $163 – $277
- Total Shares
- 61.98M
- Float Shares
- 62.11M
- Short %
- 5.92%
- % Held by Insiders
- 0.77%
- % Held by Institutions
- 102.41%
- RVOL
- 0.01x
Pipeline stages · 4 programs
Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TransCon CNP
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Navepegritide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm | Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 2 | Navepegritide | Achondroplasia | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug | Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC) | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | Navepegritide | Achondroplasia | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-04-16 | Phase 3 | Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector | Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery | — | recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2039-01 Estimated 50% readout ~2039-03-17 | Phase 2/3 | TransCon CNP | Achondroplasia | — | enrolling by invitation |
| 2025-03-28 | Phase 2 | TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ | Head and Neck Neoplasms | 27 | terminated |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $301 (+19% upside) · 18 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-05-19CitigroupBuy
- 2026-05-15Evercore ISI GroupOutperform
- 2026-05-11BarclaysOverweight
- 2026-05-08Wells FargoOverweight
- 2026-04-16B of A SecuritiesBuy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-20Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup - ChartMill
- 2026-07-19Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
- 2026-07-18Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
- 2026-07-17Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
- 2026-07-17(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
- 2026-07-16Price to earnings forward of Ascendis Pharma A/S – DUS:A710 - TradingView
- 2026-07-15Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57 - Stock Titan
- 2026-07-15Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.